FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766019856> ?p ?o ?g. }

• W2766019856 endingPage "23" @default.
• W2766019856 startingPage "14" @default.
• W2766019856 abstract "Hepatitis C virus (HCV) prevails in patients with thalassemia. We aimed to investigate the efficacy, safety, and impact on red blood cells (RBC) transfusion demand of pegylated interferon (Peg-IFN)/ribavirin therapy in thalassemic patients with HCV.This retrospective study included 18 thalassemic patients (16 with HCV-1b, one HCV-1b/2b, and one HCV-2b) and 54 consecutive sex- and genotype-matched controls. Patients with HCV-2, or HCV-1 or mixed HCV-1/2 with lower viral loads plus rapid virological response (RVR) received 24-week Peg-IFN/ribavirin; whereas HCV-1 or mixed HCV-1/2 with higher viral loads or without RVR received 48-week regimens.The rates of RVR, complete early virological response, and sustained virological response (SVR) in thalassemic patients were 72.2% (13/18), 94.1% (16/17), and 77.8% (14/18), which resembled those of controls (63.0%, 94.4%, and 81.5%, respectively). RVR was the only significant factor associated with SVR in thalassemic group, and was the strongest predictor for SVR among both groups (OR/95% CI = 14.7/2.20-98.6), followed by male gender and lower viral loads. More proportion of interleukin-28B-TT carriage were observed among thalassemic patients with SVR versus non-SVR (78.6% vs. 50.0%). Thalassemic patients experienced significantly less 80/80/80 adherence, more ribavirin reduction and serious adverse events than controls. Notably, there was a decreased post-treatment RBC transfusion demand versus baseline in thalassemic patients with SVR (5.21 vs. 5.64 units/month, p = 0.05), but not in those without SVR (6.33 vs. 6.56 units/month, p = 0.54).Peg-IFN/ribavirin was effective and tolerable for thalassemic HCV patients. Successful antiviral therapy might have extra benefit of reducing the post-treatment transfusion demand." @default.
• W2766019856 created "2017-11-10" @default.
• W2766019856 creator A5001511389 @default.
• W2766019856 creator A5009330208 @default.
• W2766019856 creator A5029851407 @default.
• W2766019856 creator A5037894997 @default.
• W2766019856 creator A5043777518 @default.
• W2766019856 creator A5057578521 @default.
• W2766019856 creator A5058609065 @default.
• W2766019856 creator A5058833990 @default.
• W2766019856 creator A5061322757 @default.
• W2766019856 creator A5062736490 @default.
• W2766019856 creator A5078365368 @default.
• W2766019856 creator A5081580592 @default.
• W2766019856 creator A5087140646 @default.
• W2766019856 creator A5090132898 @default.
• W2766019856 date "2018-01-01" @default.
• W2766019856 modified "2023-10-12" @default.
• W2766019856 title "The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C" @default.
• W2766019856 cites W1621994695 @default.
• W2766019856 cites W1975620628 @default.
• W2766019856 cites W1977300462 @default.
• W2766019856 cites W1978339383 @default.
• W2766019856 cites W1987057202 @default.
• W2766019856 cites W1995181026 @default.
• W2766019856 cites W1998859748 @default.
• W2766019856 cites W2003896680 @default.
• W2766019856 cites W2006326495 @default.
• W2766019856 cites W2021207134 @default.
• W2766019856 cites W2024144733 @default.
• W2766019856 cites W2026787165 @default.
• W2766019856 cites W2050565698 @default.
• W2766019856 cites W2058538904 @default.
• W2766019856 cites W2092710527 @default.
• W2766019856 cites W2092858485 @default.
• W2766019856 cites W2097068106 @default.
• W2766019856 cites W2111424027 @default.
• W2766019856 cites W2121745399 @default.
• W2766019856 cites W2123049088 @default.
• W2766019856 cites W2140996066 @default.
• W2766019856 cites W2142452391 @default.
• W2766019856 cites W2146392601 @default.
• W2766019856 cites W2148605666 @default.
• W2766019856 cites W2159259791 @default.
• W2766019856 cites W2169936170 @default.
• W2766019856 cites W2240375514 @default.
• W2766019856 cites W2278975800 @default.
• W2766019856 cites W2347181559 @default.
• W2766019856 cites W2468107072 @default.
• W2766019856 cites W2523065620 @default.
• W2766019856 cites W2538696745 @default.
• W2766019856 cites W2581466699 @default.
• W2766019856 cites W4211051574 @default.
• W2766019856 doi "https://doi.org/10.1016/j.jfma.2017.10.001" @default.
• W2766019856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29097076" @default.
• W2766019856 hasPublicationYear "2018" @default.
• W2766019856 type Work @default.
• W2766019856 sameAs 2766019856 @default.
• W2766019856 citedByCount "5" @default.
• W2766019856 countsByYear W27660198562018 @default.
• W2766019856 countsByYear W27660198562019 @default.
• W2766019856 countsByYear W27660198562020 @default.
• W2766019856 countsByYear W27660198562021 @default.
• W2766019856 crossrefType "journal-article" @default.
• W2766019856 hasAuthorship W2766019856A5001511389 @default.
• W2766019856 hasAuthorship W2766019856A5009330208 @default.
• W2766019856 hasAuthorship W2766019856A5029851407 @default.
• W2766019856 hasAuthorship W2766019856A5037894997 @default.
• W2766019856 hasAuthorship W2766019856A5043777518 @default.
• W2766019856 hasAuthorship W2766019856A5057578521 @default.
• W2766019856 hasAuthorship W2766019856A5058609065 @default.
• W2766019856 hasAuthorship W2766019856A5058833990 @default.
• W2766019856 hasAuthorship W2766019856A5061322757 @default.
• W2766019856 hasAuthorship W2766019856A5062736490 @default.
• W2766019856 hasAuthorship W2766019856A5078365368 @default.
• W2766019856 hasAuthorship W2766019856A5081580592 @default.
• W2766019856 hasAuthorship W2766019856A5087140646 @default.
• W2766019856 hasAuthorship W2766019856A5090132898 @default.
• W2766019856 hasBestOaLocation W27660198561 @default.
• W2766019856 hasConcept C126322002 @default.
• W2766019856 hasConcept C142462285 @default.
• W2766019856 hasConcept C197934379 @default.
• W2766019856 hasConcept C203014093 @default.
• W2766019856 hasConcept C2522874641 @default.
• W2766019856 hasConcept C2776408679 @default.
• W2766019856 hasConcept C2776455275 @default.
• W2766019856 hasConcept C2776461080 @default.
• W2766019856 hasConcept C2777799968 @default.
• W2766019856 hasConcept C2780014101 @default.
• W2766019856 hasConcept C2780040827 @default.
• W2766019856 hasConcept C71924100 @default.
• W2766019856 hasConcept C90924648 @default.
• W2766019856 hasConceptScore W2766019856C126322002 @default.
• W2766019856 hasConceptScore W2766019856C142462285 @default.
• W2766019856 hasConceptScore W2766019856C197934379 @default.
• W2766019856 hasConceptScore W2766019856C203014093 @default.
• W2766019856 hasConceptScore W2766019856C2522874641 @default.
• W2766019856 hasConceptScore W2766019856C2776408679 @default.

• next